Medicare Picked 15 More High-Cost Drugs for Price Talks. What Changes in 2026, 2027, and 2028?

Recent Medicare drug-pricing headlines have been easy to misread. When federal officials announced 15 more high-cost drugs for price negotiation on January 27, 2026, that did not mean those drugs suddenly became cheaper this year.

The practical takeaway is simpler than the headlines make it sound. One group of 10 negotiated drug prices already took effect on January 1, 2026. A second group of 15 is scheduled to take effect on January 1, 2027. The newest 15 drugs selected in January 2026 are in a third cycle, and their negotiated prices are scheduled to start on January 1, 2028.

If you or a family member takes an affected Medicare drug, the important question is not just whether a drug was mentioned in the news. It is which negotiation round it belongs to and how your own Medicare coverage handles that drug.

Quick timeline: what changed in 2026, 2027, and 2028

January 1, 2026: The first negotiated Medicare prices took effect for 10 Part D drugs. Examples include Eliquis, Jardiance, Januvia, Xarelto, and Stelara.
January 1, 2027: A second group of 15 negotiated prices is scheduled to begin. That list includes drugs such as Ozempic, Wegovy, Trelegy Ellipta, Xtandi, and Otezla.
January 27, 2026 selection for January 1, 2028: CMS selected a third group of 15 drugs for negotiation, with prices scheduled to take effect in 2028. Examples include Trulicity, Biktarvy, Botox for Medicare-covered uses, Cosentyx, and Xolair.

That is the core timeline readers need to keep straight.

Being selected is not the same as being cheaper right away

In this program, selection starts the negotiation process. It does not mark the date when lower prices begin.

According to the Centers for Medicare & Medicaid Services, the 15 drugs announced on January 27, 2026 will be negotiated during 2026, and the negotiated prices are scheduled to become effective on January 1, 2028. In other words, the announcement was the start of the next round, not the finish line.

This lag is one reason the program feels confusing. Multiple rounds can be moving at the same time. While Medicare beneficiaries are checking whether the first round changed what they pay in 2026, a second round is already lined up for 2027, and a third round is being negotiated for 2028.

AARP noted that this long runway gives plans and systems time to update coverage materials, computer systems, and formularies before new prices take effect. That helps explain why a drug can be in the news now but not show a lower Medicare price until much later.

Who may see savings now, and who may not

The people most likely to see a change now are Medicare beneficiaries who use one of the first 10 drugs whose negotiated prices took effect on January 1, 2026. But even for that group, the change is not guaranteed to look the same for everyone.

Medicare drug plans do not all work identically. Medicare explains that Part D plans use their own formularies, or covered-drug lists, and place drugs in different tiers. Those tiers affect copayments and coinsurance. Pharmacy choice can matter too, because some plans use preferred in-network pharmacies that may charge less than other pharmacies in the same plan.

So if a person takes one of the first 10 negotiated drugs, their out-of-pocket cost in 2026 may depend on several details, including:

whether the drug is on the plan formulary
what tier the drug is placed in
whether the person uses a preferred in-network pharmacy
whether the plan charges a copayment or coinsurance for that drug
other Medicare drug benefit rules that apply to that person

That is why Medicare advises beneficiaries to contact their plan for drug-specific details. A headline about lower negotiated prices does not automatically tell you what your own receipt will look like.

Why the third cycle matters: some Part B drugs are included for the first time

The January 2026 announcement matters for another reason too. CMS says this is the first negotiation cycle to include certain drugs payable under Medicare Part B, not just Part D drugs.

That distinction matters in everyday life. Part D generally covers many outpatient prescription drugs people pick up at a pharmacy. Part B often covers drugs given in a doctor’s office or outpatient setting, such as some infused or injected treatments.

Several drugs in the new third cycle fall into that office-administered category for some uses, including Botox, Cimzia, Cosentyx, Entyvio, Orencia, and Xolair. That does not mean every use of those products will work the same way under Medicare. For example, Botox appears on the list, but Medicare negotiation matters for covered medical uses, not elective cosmetic wrinkle treatment.

It also means readers should not assume the new third-cycle changes will show up the same way a retail pharmacy price might. Part B and Part D have different coverage pathways, and a lower Medicare negotiated price in 2028 may affect beneficiary costs differently depending on how a drug is covered and administered.

Why private insurance and cash prices may not follow Medicare’s timeline

Another common misunderstanding is that Medicare negotiation automatically lowers prices for everyone else. That is not how the program works.

Medicare’s negotiated “maximum fair price” applies within the Medicare program for selected drugs. It does not automatically reset what someone with employer coverage, an individual market plan, or no insurance will pay. Commercial insurers and pharmacy benefit managers negotiate separately, and cash prices can move on their own timetable.

That means a drug appearing on Medicare’s 2026, 2027, or 2028 lists does not guarantee matching savings outside Medicare. Some spillover is possible over time, but it should not be assumed.

What experts still cannot say with confidence

There is also a difference between a policy change and proof of long-term outcome effects. A recent JAMA Viewpoint discussed how real-world evidence may help Medicare drug price negotiations, but it was a policy commentary, not a clinical trial or a real-world study showing what will happen to adherence, health outcomes, or non-Medicare prices over time.

That is important context. The timeline is clear. The fact that lower negotiated prices can help many Medicare beneficiaries is clear. But the full real-world impact on behavior, access, and spending patterns will take time to measure.

What readers should do now

If you take one of the affected drugs, the most useful next step is very practical:

If your drug was in the first round, 2026 is the year to check whether your Medicare costs changed.
If your drug is in the second round, the negotiated Medicare price is scheduled for January 1, 2027.
If your drug was newly selected in January 2026, the negotiated price is expected in 2028, not now.

Then look at your own coverage details. Review your plan’s formulary, cost-sharing tier, and pharmacy rules, or call your plan and ask specifically what you would pay for that drug this year.

For readers trying to make sense of confusing headlines, the simplest bottom line is this: selection starts the process, but implementation happens later. Medicare beneficiaries may already be seeing changes in 2026 for the first 10 drugs. Another 15 are on deck for 2027. The 15 drugs selected in January 2026 are important, but their lower negotiated prices are scheduled for 2028.

Sources

This article is for general informational purposes only and is not medical advice. Research findings can be early, limited, or subject to change as new evidence emerges. For personal guidance, diagnosis, or treatment, consult a licensed clinician. For current outbreak or public health guidance, follow your local health department, the CDC, or another relevant public health authority.